Loading clinical trials...
Loading clinical trials...
Dose-attenuated IST and Hetrombopag in the Treatment of Elderly (≥65 Years) Patients With Very Severe/Severe Aplastic Anemia: A Single-Center, Single-Arm, Phase IIB Clinical Study on Efficacy and Safety
Conditions
Interventions
Dose-attenuated IST and Hetrombopag
Locations
1
China
Red Blood Cell Diseases Center
Tianjin, Tianjin Municipality, China
Start Date
February 1, 2025
Primary Completion Date
December 31, 2028
Completion Date
July 1, 2029
Last Updated
June 8, 2025
NCT07461467
NCT07381166
NCT07412379
NCT07305753
NCT07244536
NCT07041320
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions